Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

WebMD: FDA expands its partnership with the popular health information Web site WebMD with FDA-sponsored material in five new subject areas: allergies and asthma; children's health; diabetes; heart health; and vitamins and supplements. Clickable sub-topics include items titled "FDA 101: Product Recalls" and "Your Guide to Reporting Problems to FDA." Since its December 2008 launch, WebMD's FDA page has been accessed by more than 150,000 consumers, the agency notes ("1The Gray Sheet" Dec. 8, 2008)

You may also be interested in...



FDA Teams With WebMD For Wider Dissemination Of Product Safety Info

FDA will reach a vastly larger audience for product safety alerts through a new partnership with the popular health information Web site WebMD, announced Dec. 3. The pact could boost the number of patients seeing FDA alerts from 130,000 a month currently to tens of millions

ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.

‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System

Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.

Topics

UsernamePublicRestriction

Register

MT028152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel